AstraZeneca Pays Big To Get Into RSV

The UK group buys its first vaccine company, Icosavax, with an eye to its platform technology.  

Vaccine_shutterstock_1272846445_620x413.jpg

Hats off to Icosavax, Inc. – $838m isn’t a bad payday for a company with a single clinical-stage candidate. The vaccine maker has been snapped up by AstraZeneca PLC, and the sizeable upfront payment shows how eager the UK giant is to enter the respiratory syncytial virus (RSV) space, where GSK and Pfizer precede it.

Key Takeways
  • AstraZeneca has bought Icosavax for $838m upfront and potentially $1.1bn in total

AstraZeneca has structured the deal with the lion’s share of the money – $15 per share in cash – upfront....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream

 
• By 

Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.

Verona’s COPD Launch Success Sealed Merck Buyout Interest

 

SEC filings reveal that Merck was the sole bidder for Verona and its COPD drug Ohtuvayre, with the final $10bn deal wrapped up within a month.

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By 

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline

More from Business

2030’s Top Therapies: Incretin Agonists Loom Large

 

Scrip looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.

Lupin Confident Of US Growth On Tariff Mitigation, Rides High On Tolvaptan

 
• By 

Lupin is hoping moves like intellectual property transfer for some products to the US will help mitigate the tariff impact even as it counts on growth from planned launches of GLP-1s and biosimilars while riding high on tolvaptan launched in Q1.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Trump ups pressure on MFN pricing; Pfizer says pharma working with Trump on direct sales; Sanofi says direct sales worth considering: Aurigene Oncology CEO on biotech valuations and more; and Novartis progresses pipeline-in-a-product assets.